Calls to expand insurance and government coverage for in vitro fertilization (IVF) are gaining traction, but critics warn the push is not solely about helping couples facing infertility. A growing use of IVF for genetic screening has sparked debate over whether the technology is being leveraged to prevent the birth of children with certain conditions — raising ethical concerns about modern eugenics.
Key Developments
IVF advocates are pressing for government and insurance coverage of the costly procedure.
Former President Donald Trump pledged in 2024 that he would ensure IVF is funded to “produce babies in this country.”
Some couples use IVF not for infertility, but to screen embryos for genetic conditions, discarding those that test positive.
Experts and advocacy groups warn that widespread access could shift IVF from treating infertility to selecting against certain genetic traits.
Political Momentum
During his 2024 campaign, Trump promised to mandate coverage for IVF, either through government funding or insurance mandates.
“The government is going to pay for it, or we’re going to get your insurance company to pay for it,” Trump said. “We want to produce babies in this country, right?”
Ethical Debate Over Embryo Selection
IVF inherently involves selecting embryos based on laboratory assessments, but critics say the process commodifies human life. Embryo grading is widely used, though success rates remain uncertain. MedPark Hospital notes that a highly graded embryo may still fail to implant, while a lower-graded one may develop successfully.
Beyond grading, IVF is increasingly paired with preimplantation genetic diagnosis (PGD), which allows embryos to be screened for specific genetic disorders before implantation. Embryos testing positive are often discarded.
Case Study: Avoiding Polycystic Kidney Disease
A recent case drew national attention when a couple pursued IVF to avoid passing on polycystic kidney disease (PKD), a hereditary condition. The husband, living with PKD, faced a 50% chance of passing it on. With IVF and PGD, the couple created 16 embryos — 10 carried the disease and were destroyed, while six tested negative.
Their first “genetically perfect” embryo failed after transfer. The second attempt resulted in the birth of a healthy daughter in May 2025. The couple said the process cost about $60,000, supplemented by grants from the PKD-Free Alliance.
Critics argue the practice does not cure PKD but instead eliminates embryos carrying the condition. “PGD doesn’t remove disease — it removes people with the disease,” one ethicist commented.
The Role of Advocacy Groups
The PKD-Free Alliance and similar organizations provide grants for couples seeking PGD. Supporters argue the approach spares future generations from suffering. Opponents contend it promotes selective reproduction, effectively preventing children with certain genetic conditions from being born.
Stanford Medicine researchers note that PGD is now used to screen for more than 400 genetic conditions, including cystic fibrosis, Tay-Sachs disease, and sickle cell disease. While IVF with PGD costs $15,000–$25,000, lifetime care for patients with some genetic diseases can exceed $1 million. Insurers, they argue, may eventually see IVF coverage as a cost-saving measure.
Broader Implications
This cost-benefit framing has raised alarms. Critics fear IVF coverage could evolve into systemic pressure to use genetic testing — or even future mandates. Some ethicists warn such trends could normalize the expectation that families avoid natural conception if genetic risks are present.
Outlook
The debate reflects a clash between reproductive freedom, medical advancement, and ethical boundaries. IVF and PGD promise hope for many families but also raise questions about where society draws the line between preventing disease and practicing eugenics.
YOU MAY ALSO LIKE
Researchers Urge IVF Chromosome Screening on NHS for Older Women
IVF Mix-Up: Brisbane Couple Silenced After Biracial Baby Born
